Which has stronger earnings & valuation, NVAX or MRNA?

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.18 $440.30M -$1.52 N/A Moderna $1.94B 13.00 -$2.82B -$7.99 N/A

Is NVAX or MRNA more profitable?

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Moderna -141.43% -28.30% -19.39%

Does the media prefer NVAX or MRNA?

In the previous week, Moderna had 4 more articles in the media than Novavax. MarketBeat recorded 12 mentions for Moderna and 8 mentions for Novavax. Moderna's average media sentiment score of 0.35 beat Novavax's score of 0.34 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, NVAX or OCGN?

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.18 $440.30M -$1.52 N/A Ocugen $4.41M 103.42 -$67.85M -$0.26 N/A

Is NVAX or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Ocugen N/A -127,987.80% -115.95%

Does the media refer more to NVAX or OCGN?

In the previous week, Ocugen had 18 more articles in the media than Novavax. MarketBeat recorded 26 mentions for Ocugen and 8 mentions for Novavax. Novavax's average media sentiment score of 0.34 beat Ocugen's score of -0.21 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.13 $10.23B $6.69 23.38 Novavax $1.12B 1.18 $440.30M -$1.52 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Novavax -59.87% -14.82% -13.35%

Does the media favor AZN or NVAX?

In the previous week, Astrazeneca had 13 more articles in the media than Novavax. MarketBeat recorded 21 mentions for Astrazeneca and 8 mentions for Novavax. Astrazeneca's average media sentiment score of 0.86 beat Novavax's score of 0.34 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, NVAX or JNJ?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.18 $440.30M -$1.52 N/A Johnson & Johnson $94.19B 6.66 $26.80B $8.63 30.18

Is NVAX or JNJ more profitable?

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Johnson & Johnson 21.48% 32.42% 13.35%

Does the media refer more to NVAX or JNJ?

In the previous week, Johnson & Johnson had 51 more articles in the media than Novavax. MarketBeat recorded 59 mentions for Johnson & Johnson and 8 mentions for Novavax. Johnson & Johnson's average media sentiment score of 0.93 beat Novavax's score of 0.34 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 42 Very Positive mention(s) 10 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings and valuation, PFE or NVAX?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.44 $7.77B $0.76 35.23 Novavax $1.12B 1.18 $440.30M -$1.52 N/A

Is PFE or NVAX more profitable?

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Novavax -59.87% -14.82% -13.35%

Does the media favor PFE or NVAX?

In the previous week, Pfizer had 45 more articles in the media than Novavax. MarketBeat recorded 53 mentions for Pfizer and 8 mentions for Novavax. Pfizer's average media sentiment score of 0.75 beat Novavax's score of 0.34 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 21 Very Positive mention(s) 17 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Novavax (NVAX) Competitors

$8.07 -0.07 (-0.88%)

Closing price 03:59 PM Eastern

Extended Trading

$8.04 -0.03 (-0.35%)

As of 04:10 PM Eastern

Compare

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you buy Novavax stock or one of its competitors? Novavax's main competitors and comparable companies include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Novavax compare to Moderna?

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	-$1.52	N/A
Moderna	$1.94B	13.00	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 4 more articles in the media than Novavax. MarketBeat recorded 12 mentions for Moderna and 8 mentions for Novavax. Moderna's average media sentiment score of 0.35 beat Novavax's score of 0.34 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Moderna	-141.43%	-28.30%	-19.39%

53.0% of Novavax shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Novavax has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Novavax currently has a consensus target price of $13.00, suggesting a potential upside of 61.13%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 33.42%. Given Novavax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

Summary

Novavax beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Novavax (NASDAQ:NVAX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Novavax currently has a consensus price target of $13.00, indicating a potential upside of 61.13%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 606.32%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	-$1.52	N/A
Ocugen	$4.41M	103.42	-$67.85M	-$0.26	N/A

Novavax has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Ocugen had 18 more articles in the media than Novavax. MarketBeat recorded 26 mentions for Ocugen and 8 mentions for Novavax. Novavax's average media sentiment score of 0.34 beat Ocugen's score of -0.21 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Ocugen	N/A	-127,987.80%	-115.95%

Summary

Novavax and Ocugen tied by winning 8 of the 16 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novavax	-59.87%	-14.82%	-13.35%

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.13	$10.23B	$6.69	23.38
Novavax	$1.12B	1.18	$440.30M	-$1.52	N/A

Astrazeneca has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Novavax has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Astrazeneca currently has a consensus target price of $211.00, indicating a potential upside of 34.93%. Novavax has a consensus target price of $13.00, indicating a potential upside of 61.13%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Astrazeneca had 13 more articles in the media than Novavax. MarketBeat recorded 21 mentions for Astrazeneca and 8 mentions for Novavax. Astrazeneca's average media sentiment score of 0.86 beat Novavax's score of 0.34 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Astrazeneca beats Novavax on 12 of the 16 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Novavax has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Novavax currently has a consensus target price of $13.00, indicating a potential upside of 61.13%. Johnson & Johnson has a consensus target price of $268.22, indicating a potential upside of 2.99%. Given Novavax's higher possible upside, research analysts plainly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

53.0% of Novavax shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Johnson & Johnson had 51 more articles in the media than Novavax. MarketBeat recorded 59 mentions for Johnson & Johnson and 8 mentions for Novavax. Johnson & Johnson's average media sentiment score of 0.93 beat Novavax's score of 0.34 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	42 Very Positive mention(s)	10 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Johnson & Johnson	21.48%	32.42%	13.35%

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	-$1.52	N/A
Johnson & Johnson	$94.19B	6.66	$26.80B	$8.63	30.18

Summary

Johnson & Johnson beats Novavax on 14 of the 17 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Pfizer (NYSE:PFE) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Novavax has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Novavax	-59.87%	-14.82%	-13.35%

Pfizer presently has a consensus price target of $28.28, suggesting a potential upside of 5.62%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 61.13%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.44	$7.77B	$0.76	35.23
Novavax	$1.12B	1.18	$440.30M	-$1.52	N/A

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Pfizer had 45 more articles in the media than Novavax. MarketBeat recorded 53 mentions for Pfizer and 8 mentions for Novavax. Pfizer's average media sentiment score of 0.75 beat Novavax's score of 0.34 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	21 Very Positive mention(s)	17 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pfizer beats Novavax on 12 of the 17 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.33B	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-5.31	10.55	269.56	25.30
Price / Sales	1.18	1,293.72	598.74	101.64
Price / Cash	2.27	103.01	70.53	50.75
Price / Book	-6.96	17.51	13.08	6.33
Net Income	$440.30M	-$13.32M	$3.45B	$347.70M
7 Day Performance	1.48%	1.72%	1.11%	1.06%
1 Month Performance	-4.18%	1.60%	1.79%	1.03%
1 Year Performance	-14.44%	56.45%	67.70%	20.73%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	1.6572 of 5 stars	$8.07 -0.9%	$13.00 +61.1%	-8.0%	$1.33B	$1.12B	N/A	1,990
MRNA Moderna	1.3524 of 5 stars	$55.14 +0.6%	$42.13 -23.6%	+136.7%	$21.88B	$2.21B	N/A	4,700
OCGN Ocugen	1.8046 of 5 stars	$1.25 +1.6%	$9.50 +660.0%	+31.1%	$423.15M	$4.47M	N/A	80	Analyst Upgrade Analyst Revision
AZN Astrazeneca	4.9196 of 5 stars	$158.21 -6.7%	$211.00 +33.4%	+0.8%	$245.37B	$61.37B	23.65	96,100	Analyst Revision High Trading Volume
JNJ Johnson & Johnson	4.8022 of 5 stars	$254.54 -0.7%	$267.48 +5.1%	+50.6%	$613.41B	$94.19B	29.49	138,200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors